Completed OBSERVATIONAL NCT02006862

eVAluatIon of OLanzapine TreatmEnT (VIOLET)

Olanzapine in Standard Clinical Practice. 6-month Efficacy and Safety Monitoring

Sponsor: Elpen Pharmaceutical Co. Inc.

Conditions Bipolar Disorder Schizophrenia

Updated 6 times since 2017 Last updated: Mar 13, 2015 Started: Jan 31, 2014 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Bipolar Disorder and Schizophrenia and is currently completed. Elpen Pharmaceutical Co. Inc. leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elpen Pharmaceutical Co. Inc.

Data source: Elpen Pharmaceutical Co. Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece